Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

Xizang Haisco Pharma Completes $127 Million IPO

publication date: Jan 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Xizang Haisco Pharmaceutical Group, which produces TCM drug formulations and active pharmaceutical ingredients, completed a $127 million IPO on Shenzhen’s Small and Medium-Sized Enterprises Board. The company, located in China’s autonomous Tibet region, is the 11th Tibetan entity to become publicly owned. CITIC Securities was the lead underwriter. More details....

Stock Symbol: (SHE: 002653)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Investor Forum
2013-Shanhai
September 4-5,2013
Shanghai, China

ChinaBio® Leadership Retraet
2013-Suzhou
October 24-25, 2013
Suzhou, China

ChinaBio® Investor Forum
2013-Wuhan
December 4-5,2013
Wuhan, China
>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

China Forum 2013
November 3, 2013
Vienna, Austria

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners